Bio Path Holdings Inc
biopathholdings.comWhat Do They Do?
Develops nanoparticle drug candidates that target disease-related proteins for cancer and obesity, and offers its drug-delivery technology for licensing or partnerships with pharmaceutical companies.
10-K for FY2024, filed Mar 27, 2025We are a clinical and preclinical stage oncology and obesity-focused RNAi nanoparticle drug development company utilizing a novel…View ↗
Our DNAbilize® technology-based products are available for out-licensing or partnering. We intend to apply our drug technology template to…View ↗
Our basic drug development concept is to block expression of proteins associated with disease. Messenger RNA (“mRNA”) is essential in the…View ↗
Who Are Their Customers?
The company has no commercial drug products; its candidates and technology may be out-licensed or partnered, and approved products could be sold by Bio-Path in focused physician markets or through other companies in broader markets.
10-K for FY2024, filed Mar 27, 2025Our DNAbilize® technology-based products are available for out-licensing or partnering. We intend to apply our drug technology template to…View ↗
Sales and MarketingView ↗
We currently do not have any commercial drug products or an organization for the sales and marketing of pharmaceutical products. In order…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2026, filed May 20, 2026
−$270KView ↗
- ▼ −91% (Loss)
- vs −$2.9M in Q1 FY2025
-
Jul 16, 2026
Bio-Path made Himalaya Technologies a majority-owned subsidiary
Himalaya operates a crypto social site and trading platform under development.
Sources
8-K, filed Jul 16, 2026
On July 6, 2026, we issued 22,342 Series B Preferred shares (subscription payable) for 2,3125,000 Series B Preferred shares and 51 Series M…View ↗
-
Oct 29, 2025
Vikram Grover became president, CEO and CFO
Sources
8-K, filed Oct 29, 2025
On October 22, 2025, the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) elected and appointed Vikram Grover as…View ↗
-
Aug 13, 2025
Bio-Path dismissed Ernst & Young as its auditor
Sources
8-K, filed Aug 13, 2025
On August 13, 2025, the Board of Directors of Bio-Path Holdings, Inc. (the “Company”) approved the dismissal of Ernst & Young LLP (“EY”) as…View ↗
-
Jun 24, 2025
The CEO, CFO and chair resigned
Sources
8-K, filed Jun 24, 2025
On June 20, 2025, Peter H. Nielsen notified the Board of Directors (the “Board”) of Bio-Path Holdings, Inc. (the “Company”) of his decision…View ↗
Expansion into metabolic disease
The older report described an oncology-focused pipeline; the latest also presents a modified prexigebersen candidate as a potential treatment for obesity and related metabolic diseases.
10-K for FY2021, filed Mar 10, 2022 10-K for FY2024, filed Mar 27, 2025Insulin resistance is a major contributor to obesity, Type 2 diabetes and other related metabolic diseases. Scientific evidence suggests…View ↗
Loading...
